Browse the corpus

Heart-lung transplantation is a complex surgical procedure reserved for patients with end-stage heart and lung diseases that are refractory to other treatments. Indications often include conditions such as pulmonary hypertension, congenital heart defects with severe pulmonary involvement, and advanced interstitial lung disease. The procedure involves replacing both the heart and lungs with those from a single donor, offering the possibility of extended survival and improved quality of life. However, heart-lung transplantation carries significant risks, including organ rejection, infection, and complications related to immunosuppressive therapy, making it a challenging yet life-saving intervention. Clinicians participating in this course gain a comprehensive understanding of the indications, surgical techniques, and postoperative management of heart-lung transplant cases. The course enhances the clinician's ability to address psychosocial and behavioral factors that impact long-term transplant success, ultimately improving patient care and safety. Further, through this course, clinicians learn to identify and manage potential complications, apply best practices for optimizing patient outcomes, and appreciate the critical role of interprofessional collaboration in providing holistic care. Objectives: Identify appropriate candidates for heart-lung transplantation based on clinical, functional, and psychosocial criteria. Assess for signs of transplant rejection and other posttransplant complications using clinical and diagnostic tools. Differentiate between indications and contraindications for heart-lung transplantation to optimize patient selection. Communicate the importance of improving care coordination amongst the interprofessional team to enhance heart-lung transplant outcomes. Access free multiple choice questions on this topic.

Pioneered in the 1960s and successfully implemented in the 1980s, with a declining number of candidates since the 1990s, simultaneous heart and lung transplantation is only indicated for patients in the end stages of both cardiac and pulmonary failure.[1] Suppose only 1 of the 2 thoracic organ systems has irreversibly failed, and the other is salvageable. In that case, most treatment centers forego dual transplants as the risk-benefit analyses suggest salvage should be attempted, and only the irreversibly failed organ should be replaced. This strategy spares the patient the cumulative risk of 2 simultaneous transplants, shortens their time on the waiting list, and allocates more organs to more patients.[2][3][4][3] Therefore, in the current era, most patients are preferentially placed as candidates for either lung transplant or advanced heart failure therapies, including mechanical circulatory support and heart transplant. In 2014, the United Network for Organ Sharing initiated a critical review of its heart transplantation donor allocation policy. This review was driven by several factors, including a growing imbalance between organ availability and demand, high mortality rates among the sickest patients on the waitlist, and an increase in candidates being bridged to transplant with left ventricular assist devices. The thoracic subcommittee expanded the number of priority tiers to 6 in the revised allocation policy to address these concerns, allowing for more precise risk stratification and reducing the need for status exceptions. While the subcommittee considered posttransplant survival, the main goal of the new system was to reduce mortality among waitlisted patients.[5] Allocation Tiers and Descriptions Tier 1 Veno-arterial extracorporeal membrane oxygenation Nondischargeable biventricular assist device (BiVAD) Mechanical circulatory support (MCS) with arrhythmia Tier 2 Dischargeable right ventricular assist device/BiVAD Nondischargeable left ventricular assist devices (LVAD) Intraaortic balloon pump or other percutaneous MCS MCS with malfunction Tier 3 Continuous intravenous (IV) inotropes with hemodynamic monitoring 30-day exception period for LVAD MCS with complications Tier 4 Continuous IV inotropes without hemodynamic monitoring Stable LVAD Congenital heart disease Restrictive cardiomyopathy Retransplantation Tier 5 Multiorgan transplant Tier 6 All other candidates

Intraaortic balloon pump or other percutaneous MCS MCS with malfunction Tier 3 Continuous intravenous (IV) inotropes with hemodynamic monitoring 30-day exception period for LVAD MCS with complications Tier 4 Continuous IV inotropes without hemodynamic monitoring Stable LVAD Congenital heart disease Restrictive cardiomyopathy Retransplantation Tier 5 Multiorgan transplant Tier 6 All other candidates Despite the advancements in organ transplantation and donor allocation strategies, heart-lung transplantation remains a rare and complex procedure, with only about 100 new cases reported annually.[3] The challenges associated with patient selection, donor availability, and postoperative management necessitate a highly coordinated and multidisciplinary approach. Given the limited number of cases and stringent indications, healthcare professionals must stay informed about evolving guidelines, allocation policies, and therapeutic alternatives. This introduction aims to provide a comprehensive understanding of the unique considerations and current state of heart-lung transplantation, serving as a foundation for in-depth discussions on patient management, surgical techniques, and long-term outcomes in this niche area of transplant medicine.

Patients with a heart-lung transplant are at risk for a multitude of early complications, as would be expected after major thoracic transplant surgery. In particular, primary graft dysfunction of the lung from ischemic reperfusion injury results in increasingly severe hypercapnia and hypoxia, with an incidence of 15% to 20% after 48 to 72 hours.[17] Primary cardiac graft failure, defined by severe sustained hemodynamic status without alternative explanation, is another high-risk complication with an incidence of up to 22% and mortality of 53% and seems to be more associated with idiopathic hypertension and sarcoidosis in the recipient.[17] As with any tracheal surgery, the patient is at risk of acute airway emergencies, but this incidence has been reported to be reasonably low, cited to be 3.8% in 1993.[20] Later complications arise from the transplant conundrum of balancing immune suppression, infections, and medication adverse events against the risk of rejection. Chronic rejection of the lung graft manifested as bronchiolitis obliterans syndrome occurs in 7% and 31% of patients at 1 and 5 years, respectively.[21] Chronic rejection of the heart graft, manifesting as coronary artery vasculopathy, occurs in 8%.[16] Immunosuppression protocols and rejection surveillance with echocardiography (with endomyocardial biopsy considered if echocardiography is abnormal), surveillance bronchoscopy with endobronchial biopsy, and spirometry remain center-specific and patient-dependent.[8] Immune suppression must be carefully titrated because, on the other side of the balance, infection in these patients has historically caused 40% of all mortality, with fungal infections being prevalent in the first month and involved in up to 14% of infectious complications.[22]

Immunosuppression protocols and rejection surveillance with echocardiography (with endomyocardial biopsy considered if echocardiography is abnormal), surveillance bronchoscopy with endobronchial biopsy, and spirometry remain center-specific and patient-dependent.[8] Immune suppression must be carefully titrated because, on the other side of the balance, infection in these patients has historically caused 40% of all mortality, with fungal infections being prevalent in the first month and involved in up to 14% of infectious complications.[22] Medication-induced adverse events are also common in a high percentage of transplant recipients, eg, 88% with posttransplant hypertension, 70% with hyperlipidemia, 17% to 27% with diabetes, and 46% with renal dysfunction—with 2% to 4% progressing to dialysis.[16][21] These patients must also be monitored for posttransplant malignancies, especially posttransplant lymphoproliferative disorder, which seems to have a higher incidence of 7.6% in those with heart-lung transplant, compared to 5.4% with heart transplant alone and in the lung without heart (3.1%). This complication may occur within the first year.[8] There has been some enthusiastic speculation that multiorgan transplants may have an increased tendency to promote recipient tolerance to the donor organs, in contrast with a single organ transplanted alone. However, this hypothesis does not seem supported in a heart-lung transplant.[21] Several complications may arise from a complicated surgical dissection. Injury or excess manipulation of the vagus nerves may lead to gastroparesis, gastroesophageal reflux disease, and aspiration. These conditions can be quite adverse to the lung graft and are risk factors for bronchiolitis obliterans syndrome. Injury to the phrenic nerves may result in diaphragmatic paresis manifesting as acute to chronic dyspnea; injury to the thoracic duct may lead to chylothorax.[8]

A heart-lung transplant, as a highly complex and life-altering intervention, demands the coordinated efforts of a dynamic, multifaceted team. This team typically includes surgeons, cardiologists, pulmonologists, anesthesiologists, nurses, transplant pharmacists, physical and occupational therapists, respiratory therapists, dietitians, social workers, and clinical psychologists. Each healthcare professional plays a critical role, from preoperative assessments to postoperative care. Effective collaboration and interprofessional communication are crucial to ensuring patient-centered care, minimizing complications, and improving long-term outcomes. For instance, pharmacists ensure proper immunosuppressive therapy, while dietitians and therapists promote recovery and physical function. Social workers and psychologists help address psychosocial, behavioral, and demographic factors, which are increasingly recognized as important for long-term transplant success.[24] Care coordination among team members is pivotal in navigating the intricate transplant process, where even minor miscommunications can lead to adverse outcomes. Psychosocial, demographic, and behavioral factors are now recognized as significant determinants of long-term survival in transplant recipients.[25] Thus, the team must work closely with patients and their families, offering education and support to ensure adherence to posttransplant care plans and lifestyle modifications. This collaborative approach enhances patient-centered care, improves long-term outcomes, and promotes team performance, ensuring patients receive the highest standard of care throughout their transplant journey.